Dr. Samuel Pang (he/him) is a board-certified Reproductive Endocrinologist at Boston IVF. He specializes in all aspects of fertility care.
Dr. Pang is not accepting new patients. Please view our other fertility specialists.
Telehealth Consults
Available to patients in Massachusetts
In-person Consults
Dr. Pang is not accepting new patients. Please view our other fertility specialists.
Dr. Samuel Pang is double board-certified in Obstetrics and Gynecology/Reproductive Endocrinology and Infertility. He specializes in all aspects of infertility and family-building care. Dr. Pang is a leader of Boston IVF's Third Party Reproduction Program, which provides important care and treatments for patients in need of donor egg and/or a gestational surrogate. He is the recipient of eleven consecutive Top Fertility Doctor awards by Boston Magazine (2012-2022).
Dr. Pang completed his residency in Obstetrics and Gynecology at the University of Toronto, Canada and his fellowship in Reproductive Endocrinology and Infertility from the UCLA School of Medicine in California. A past Assistant Professor of Gynecology and Obstetrics at Loma Linda University School of Medicine, he currently is a Fellow of the Royal College of Physicians & Surgeons of Canada, as well as a Fellow of the American College of Obstetricians & Gynecologists.
Dr. Pang has also served as Chief of Obstetrics and Gynecology at the Deaconess Waltham Hospital. Dr. Pang is a Licentiate of the Medical Council of Canada, as well as a diplomat of the National Board of Medical Examiners in the United States. He has served as president of the New England Fertility Society, and has published numerous research and clinical papers in the areas of menopause, infertility, assisted reproductive technologies, and Andrology. He has a special interest in the management of male infertility as well as third party reproductive options. Dr. Pang spends time with his two sons who were conceived through IVF. He is truly able to appreciate the process of IVF treatment from both the patient and physician perspective.
Recent Selected Publications 1. Zhao J, Zahn A, Pang SC, Quang TS, Campbell J, Halkitis PN. Early national trends in non-abortion reproductive care access after Roe. Front Public Health. 2024 Mar 8;12:1309068. doi: 10.3389/fpubh.2024.1309068. PMID: 38525331; PMCID: PMC10957616. 2. Munné S, Kaplan B, Frattarelli JL, Child T, Nakhuda G, Shamma FN, Silverberg K, Kalista T, Handyside AH, Katz-Jaffe M, Wells D, Gordon T, Stock-Myer S, Willman S; STAR Study Group. Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial. Fertil Steril. 2019 Dec;112(6):1071-1079.e7. doi: 10.1016/j.fertnstert.2019.07.1346. Epub 2019 Sep 21. PMID: 31551155. 3. Leung A, Sakkas D, Pang S, Thornton K, Resetkova N. Assisted reproductive technology outcomes in female-to-male transgender patients compared with cisgender patients: a new frontier in reproductive medicine. Fertil Steril. 2019 Nov;112(5):858-865. doi: 10.1016/j.fertnstert.2019.07.014. Epub 2019 Oct 6. PMID: 31594633. 4. Munné S, Kaplan B, Frattarelli JL, Child T, Nakhuda G, Shamma FN, Silverberg K, Kalista T, Handyside AH, Katz-Jaffe M, Wells D, Gordon T, Stock-Myer S, Willman S; STAR Study Group. Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial. Fertil Steril. 2019 Dec;112(6):1071-1079.e7. doi: 10.1016/j.fertnstert.2019.07.1346. Epub 2019 Sep 21. PMID: 31551155. 5. Liu C, Politch JA, Cullerton E, Go K, Pang S, Kuohung W. Impact of daylight savings time on spontaneous pregnancy loss in in vitro fertilization patients. Chronobiol Int. 2017;34(5):571-577. doi: 10.1080/07420528.2017.1279173. Epub 2017 Feb 3. PMID: 28156172. 6. Boostanfar R, Mannaerts B, Pang S, Fernandez-Sanchez M, Witjes H, Devroey P; Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone. Fertil Steril. 2012 Jun;97(6):1351-8. doi: 10.1016/j.fertnstert.2012.02.038. Epub 2012 Mar 28. PMID: 22459628. 7. Pang, Samuel. (2005). Use of follicle-stimulating hormone for the treatment of female infertility – current concepts. Women's health (London, England). 1. 87-95. 10.2217/17455057.1.1.87. 8. Pang, Samuel. (2005). Use of Follicle-Stimulating Hormone for the Treatment of Female Infertility – Current Concepts. Women's Health. 1. 87-95. 10.1517/17455057.1.1.087. 9. Ellison MA, Hotamisligil S, Lee H, Rich-Edwards JW, Pang SC, Hall JE. Psychosocial risks associated with multiple births resulting from assisted reproduction. Fertil Steril. 2005 May;83(5):1422-8. doi: 10.1016/j.fertnstert.2004.11.053. PMID: 15866579. 10. Pang, Samuel. (2005). A pen injection device for self-administration of recombinant follicle-stimulating hormone for fertility treatments. Expert review of medical devices. 2. 27-32. 10.1586/17434440.2.1.27.